For Black Americans, the battle with Chronic Myeloid Leukemia is marked by unique survival challenges and treatment ...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...

New Innovative Local Treatment for Osteolytic Bone Disease ... untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases ...

Dasatinib is prescribed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults.

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

In The Lancet Hematology, Jorge E Cortes and colleagues1 report a phase 1/2 study on vodobatinib in patients with resistance ...

Zydus Lifesciences added 3.33% to Rs 917.10 after the company said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture generic Dasatinib ...

Tyrosine kinase inhibitors (TKIs) to BCR-ABL1 have been successfully used to treat chronic myeloid leukemia (CML), however, multiple TKI-associated adverse events ... several clinical stage kinase ...

Ascentage Pharma’s olverembatinib gets China NMPA’s BTD to treat Philadelphia chromosome-positive acute lymphoblastic leukemia: Rockville Friday, March 7, 2025, 11:00 Hrs [IST ...

Venetoclax (Brand name: Venclexta) is a targeted treatment for chronic lymphocytic leukemia (CLL). It targets a specific protein called BCL-2 in cancer cells that helps them stay alive. Doctors ...